Abstract
In 1977, percutaneous transluminal coronary angioplasty (PTCA) was first introduced (1), and it has become an effective treatment for limited coronary artery disease (2). PTCA treatment has since become more extensive and gained favor as an alternative treatment for coronary artery bypass grafting (3). The artery is injured at the site of PTCA, leading to wound healing responses including thrombosis, smooth muscle proliferation and migration, elastic recoil, and vascular remodeling. Each of these responses may contribute to recurrent obstruction or vessel narrowing, referred to as restenosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gruntzig, A. R., Senning, A., and Siegenthaler, W. E. (1977) Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301, 61–68.
Parisi, A. F., Folland, E. D., and Hartigan, P. (1992) A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: veterans Affairs ACME Investigators. N. Engl. J. Med. 326, 10–16.
King, S. B., Lembo, N. J., and Weintraub, W. S. (1994) A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N. Engl. J. Med. 331, 1044–1050.
Zalewski, A., Shi, Y., Mannion, J. D., et al. (1998) Synthetic DNA-based compounds for the prevention of coronary restenosis: current status and future challenges. In Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors (Wickstrom, E., ed.), Marcel Dekker New York, pp. 363–393.
Serruys, P., Kutryk, M. J. B., Bruining, N., et al. (1998) Antisense oligonucleotide against c-myc administered with the Transport delivery catheter for the prevention of in-stent restenosis: results of the randomized ITALICS trial. Suppl. Circ. Sci. Sessions Abstr. 98(17), I-1–I-1016.
Hudziak, R. M., Summerton, J., Weller, D. D., and Iversen, P. L. (2000) Antiproliferative effects of steric blocking phosphorodiamidate Morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Devel. 10, 163–176.
Dani, C, Blanchard, J. M., Piechaczyk, M., El Sabouty, S., Marty, L., and Jeanteur, P. (1984) Extreme instability of myc mRNA in normal and transformed human cells. Proc. Natl. Acad. Sci. USA 81, 7046–7050.
Hann, S. R. and Eisenman, R. N. (1984) Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol. Cell. Biol. 4, 2486–2497.
Waters, C. M., Littlewood, T. D., Hancock, D. C, Moore, J. P., and Evan, G. I. (1991) c-myc protein expression in untransformed fibroblasts. Oncogene 6, 797–805.
Miano, J. M., et al. (1991) Smooth muscle cell immediate early gene and growth factor activation follows vascular injury: a putative mechanism for autocrine growth. Atheroscl. Thromb. 13, 211–219.
Simons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R., and Rosenberg, R. D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359, 67–80.
Morishita, R., Gibbons, G. H., Ellison, K. E., et al. (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90, 8474–8478.
Shi, Y., Fard, A., Galeo, A., et al. (1994) Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation 90, 944–951.
Cornish, K. G, Iversen, P. L., Smith, L., Arneson, M., and Bayever, E. (1993) Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3, 239–247.
Galbraith, W. M., Hobson, W. C, Giclas, P. C, Schechter, P. J., and Agrawal, S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201–206.
Wallace, T. L., Bazemore, S. A., Kornburst, D. J., and Cossum, P. A. (1996) Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomologousd monkeys. J. Pharmacol. Exp. Ther. 278, 1306–1312.
Henry, S. P., Bolte, H., Auletta, C, and Kornburst, D. J. (1997) Evaluation of the toxicity of ISIS 2302 a phosphorothioate oligonucleotide, in a four week study in cynamologous monkeys. Toxicology 120, 145–155.
Iversen, P. L., Cornish, K. G, Iversen, L. J., Mata, J. E., and Bylund, D. B. (1999) Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as a1-adrenergic receptor antagonists. Toxicol. Appl. Pharmacol. 160, 289–296.
Kipshidze, N., Keane, E., Stein, D., et al. (2001) Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Cathet. Cardiovasc. Interventions 54, 247–256
Kipshidze, N. N., Kim, H.-S., Iversen, P. L., et al. (2002) Intramural delivery of advanced antisense oligonucleotides with infiltrator cathetor inhibits c-myc expression and intimal hyperplasia in the porcine. J. Am. Coll. Cardiol. 39(10), 1686–1691.
Sheppard, R. and Eisenberg, M. J. (2001) Intracoronary radiotherapy for restenosis. N. Engl. J. Med. 344(4), 295–297.
Herdeg, C, Oberhoff, M., Baumbach, A., et al. (2000) Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. Cardiol. 35(7), 1969–76.
Sousa, J. E., Costa, M. A., Abizaid, A., et al. (2001) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103(2), 192–195.
Porter, T. R., Iversen, P. L., Li, S., and Xie, F. (1996) Interaction of Diagnostic Ultrasound with Synthetic Oligonucleotide-Labeled Perfluorocarbon-Exposed Sonicated Dextrose Albumin Microbubbles. J. Ultrasound Med. 15, 577–584.
Porter, T. R., Hiser, W., Kricsfeld, D., Xie, F., Iversen, P., and Radio, S. (2000) Inhibition of carotid artery neointimal formation with intravenous microbubbles. Ultrasound Med. Biol. 27, 259–265.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Iversen, P.L., Kipshidze, N., Moses, J.W., Leon, M.B. (2005). Local Application of Antisense for Prevention of Restenosis. In: Phillips, M.I. (eds) Antisense Therapeutics. Methods in Molecular Medicine™, vol 106. Humana Press. https://doi.org/10.1385/1-59259-854-4:037
Download citation
DOI: https://doi.org/10.1385/1-59259-854-4:037
Publisher Name: Humana Press
Print ISBN: 978-1-58829-205-6
Online ISBN: 978-1-59259-854-0
eBook Packages: Springer Protocols